Effector Therapeutics
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
eFFECTOR Therapeutics was a Solana Beach and Redwood City, California biotechnology company pioneering selective translation regulator (STR) therapeutics for cancer. Its clinical programs included zotatifin (eFT226), an eIF4A inhibitor, and tomivosertib (eFT508), an MNK1/2 inhibitor, studied in solid tumors. The company went public on Nasdaq (ticker EFTR) via a SPAC merger in 2021.
02 / Effector Therapeutics FAILURE REASONS
Failure factors
frames eFFECTOR’s company wind-down as following the April 2024 Phase 2b KICKSTART failure of tomivosertib in frontline NSCLC (company: no obvious path forward). Concurrent SEC EX-99.1 wind-down release (24 Jun 2024) warns lender may accelerate loan repayment expected to exceed available capital, with pledged assets senior to common stockholders in any liquidation.
April 2024 Phase 2b KICKSTART: tomivosertib+pembrolizumab did not meet pre-specified PFS threshold; company said no obvious path forward in frontline NSCLC (company release republished via BioSpace/Fierce).
Company wind-down EX-99.1 (24 Jun 2024) states lender may declare default and accelerate repayment expected to exceed current available capital, with senior claim on pledged assets in liquidation.
03 / EVENT HISTORY
Events in the structured record
- Operations ended
The company announced a wind-down on 24 June 2024, terminated its employees and appointed a specialist to manage the process.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
On June 24, 2024, eFFECTOR Therapeutics announced that it had terminated its employees and would wind down its operations, including seeking potential strategic alternatives for its development programs.
- 02
The decision was made at a special meeting of the board of directors; the company also planned to voluntarily request delisting of its securities from Nasdaq.
- 03
The board appointed Craig R. Jalbert — a principal of Verdolino & Lowey with over 30 years of experience in distressed businesses — as CEO, President, Treasurer, Secretary, and sole board member to oversee the wind-down.